    HUDSON, Mass. and YOKNEAM ILLIT, Israel, March  25, 2026  (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) (&#34;Lifeward&#34; or the &#34;Company&#34;), a global leader in innovative medical technology to transform the lives of

LFWD

Lifeward Successfully Closes on Strategic Partnership with Oramed

Lifeward Secures Strategic Partnership with Oramed Pharmaceuticals

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>HUDSON, Mass. and YOKNEAM ILLIT, Israel, March  25, 2026  (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) (&amp;#34;Lifeward&amp;#34; or the &amp;#34;Company&amp;#34;), a global leader in innovative medical technology to transform the lives of</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Lifeward Ltd. has finalized its strategic partnership with Oramed Pharmaceuticals, gaining access to significant capital and technology. This acquisition strengthens Lifeward’s position in the biomedical space and enhances prospects for profitability in the long term.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>LFWD closed a strategic partnership with Oramed Pharmaceuticals.</li><li>The partnership grants LFWD access to $47 million in capital.</li><li>LFWD acquired Oramed&#039;s oral delivery technology, expanding its biotech portfolio.</li><li>Management changes were made following the transaction completion.</li><li>The deal positions LFWD for a clearer path to profitability.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Oramed Pharmaceuticals Inc. (ORMP)</strong>: Partnership positions LFWD competitively in the biotech sector.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The news fits into Corporate Developments as it highlights a strategic partnership aimed at expanding LFWD&#039;s market reach and financial stability, which could lead to a notable shift in growth trajectory.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Access to $47 million can accelerate product development and commercialization.</li><li>Acquisition of Oramed&#039;s technology opens high-growth biotech opportunities.</li><li>Management changes may affect corporate strategy and execution speed.</li><li>Market response may shift positively towards enhanced innovation forecasts.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Lifeward accessed $10 million of the $47 million in capital on March 25, 2026.</li><li>The strategic partnership with Oramed is now finalized.</li><li>Lifeward is entering a new segment with Oramed&#039;s Protein Oral Delivery technology.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying LFWD shares as new partnership enhances growth potential over the next 12 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify" style="text-align: justify;">  </p>  <p align="justify">HUDSON, Mass. and YOKNEAM ILLIT, Israel, March  25, 2026  (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/LFWD">LFWD</a>) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company's previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ORMP">ORMP</a>).</p>  <p align="justify">The transaction has positioned Lifeward as a diversified biomedical innovation company with an expected clear path to profitability. Lifeward acquired Oramed's clinical-stage Protein Oral Delivery (POD&#x2122;) technology, adding exposure to a large, long-term biotech market opportunity. Through the new partnership, Lifeward has access to up to $47 million of capital from Oramed and certain investors, and on March 25, 2026 Lifeward accessed $10 million of such capital. The Company has also made changes to its board of directors. More information about the closing of the transaction may be viewed in Lifeward's Form 8-K filed on March 2<span dir="RTL">5</span>, 2026.</p>  <p><strong>About Lifeward</strong></p>  <p align="justify">Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the MyoCycle FES System, and the ReStore Exo-Suit.</p>  <p>Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.</p>  <p>Lifeward<sup>&#xAE;</sup>, ReWalk<sup>&#xAE;</sup>, ReStore<sup>&#xAE;</sup> and Alter G<sup>&#xAE;</sup> are registered trademarks of Lifeward Ltd. and/or its affiliates.</p>  <p><strong>Forward-Looking Statements</strong></p>  <p align="justify">In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934 concerning Lifeward, Oramed, the strategic investment and partnership agreement with Oramed (collectively, the "Proposed Transactions") and other matters. Such forward-looking statements may include projections regarding the Company&#39;s future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like &#34;anticipate,&#34; &#34;assume,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;future,&#34; &#34;will,&#34; &#34;should,&#34; &#34;would,&#34; &#34;seek&#34; and similar terms or phrases. The forward-looking statements contained in this press release are based on management&#39;s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. Important factors that could cause the Company's actual results to differ materially from those indicated in the forward-looking statements include, among others: Lifeward's management team's expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the perceived benefits or opportunities of the Proposed Transactions; expectations regarding the use of proceeds; the future operations of Lifeward, including research and development activities; the nature, strategy and focus of Lifeward; anticipated clinical drug development activities and related timelines, and other clinical results; the sufficiency of post-transaction resources to support the advancement of Lifeward's pipeline through certain milestones and the time period over which Lifeward's post-transaction capital resources will be sufficient to fund its anticipated operations; unexpected costs, charges or expenses resulting from the Proposed Transactions; potential adverse reactions or changes to business relationships resulting from the completion of the Proposed Transactions; and legislative, regulatory, political and economic developments; the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company&#39;s ability to have sufficient funds to meet certain future capital requirements, which could impair the Company&#39;s efforts to develop and commercialize existing and new products; the Company&#39;s ability to maintain and grow its reputation and the market acceptance of its products; the Company&#39;s ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company&#39;s limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company&#39;s expectations as to its clinical research program and clinical results; the Company&#39;s expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company&#39;s ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company's ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company&#39;s ability to improve its products and develop new products; the Company&#39;s compliance with medical device reporting regulations to report adverse events involving the Company&#39;s products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company&#39;s ability to market and sell its products; the Company&#39;s ability to gain and maintain regulatory approvals; the Company&#39;s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company&#39;s IT systems significantly disrupting its business operations; the Company&#39;s ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading &#34;Risk Factors&#34; in the Company's annual report on Form 10-K, as amended, for the year ended December 31, 2025 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</p>  <p><u>Contact:</u><br></br>Almog Adar<br></br>Chief Financial Officer</p>  <p align="left" dir="RTL"><span dir="LTR">Lifeward</span></p>  <p>E: media@golifeward.com<br></br>E: ir@golifeward.com</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3ODUxMCM3NTAzNDc2IzIwMTExODM="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NGUwMmUzZjUtMjNjMy00ZDhlLWJjNDktYTQ1ODFkMzA5NGEwLTEwMjI3NTYtMjAyNi0wMy0yNS1lbg==/tiny/Lifeward-Ltd-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/9343d7ac-5bc7-4a60-a2c9-a41bf7b5e007"><img src="https://ml.globenewswire.com/media/9343d7ac-5bc7-4a60-a2c9-a41bf7b5e007/small/lifeward-full-logo-rgb-for-web-01-jpg.jpg" border="0" width="150" height="107" alt="Primary Logo"></img></a></p>

Lifeward Ltd. has finalized its strategic partnership with Oramed Pharmaceuticals, gaining access to significant capital and technology. This acquisition strengthens Lifeward’s position in the biomedical space and enhances prospects for profitability in the long term.

Lifeward Successfully Closes on Strategic Partnership with Oramed

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News